By Fineline Cube 
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with several independent third-parties regarding three potential licensing deals. These deals involve an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) and other drug candidates developed using CSPC’s proprietary technology platforms. The proposed collaborations would cover development, manufacturing, and commercialization rights.
Potential Deal Structure and Value
Each potential transaction could include upfront payments, development milestone payments, and commercialization milestone payments. The total aggregate value of these deals could potentially reach USD 5 billion, highlighting the significant potential of CSPC’s drug candidates and technology platforms in the global market.
Progress and Timeline
One of the three deals has now progressed to late-stage negotiations and is expected to be finalized by June 2025. CSPC emphasized that the specific terms and conditions remain under discussion. The company will issue further announcements as appropriate, ensuring transparency for stakeholders.-Fineline Info & Tech